Inclisiran and Lipfendra are changing cholesterol management, with new guidelines from the American Heart Association and American College of Cardiology.

The FDA has approved Lipfendra, a new oral PCSK9 inhibitor, and a systematic review found that inclisiran reduces LDL cholesterol by 49% more than placebo. New guidelines from the American Heart Association and American College of Cardiology are also changing how high cholesterol is treated.

Inclisiran and LDL Cholesterol

A new systematic review and meta-analysis found that inclisiran led to a 49% greater reduction in LDL cholesterol compared with placebo. The analysis examined nine randomized controlled trials and found consistent reductions in LDL cholesterol among people receiving different background lipid-lowering therapies, including statins. Inclisiran is a synthetic drug that targets the synthesis of certain proteins that can increase LDL levels.

Lipfendra Approval and Efficacy

The FDA approved Lipfendra, the first oral PCSK9 inhibitor for adults with high LDL cholesterol, on July 16. The once-daily pill can be used in addition to or instead of statins. In two clinical trials, Lipfendra lowered LDL cholesterol by about 56% after 24 weeks in one study and 59% in the other. While the trials did not examine whether the drug reduces the risk of heart attack or stroke, the FDA accepts reductions in LDL cholesterol as a validated surrogate marker for lower cardiovascular risk.

Updated Cholesterol Guidelines

The American Heart Association, American College of Cardiology, and several other medical organizations introduced new guidelines for the management and screening of high cholesterol earlier in 2026. The guidelines recommend treating high cholesterol earlier, measuring lipoprotein(a) at least once to help identify inherited heart disease risk, and using a newer risk calculator to better estimate cardiovascular risk. Studies on the impacts of these guidelines found that over 50% of adults in the United States may now be eligible for statins.